Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124653323 | 12465332 | 3 | F | 20160104 | 20160920 | 20160614 | 20160927 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-045777 | BRISTOL MYERS SQUIBB | 65.00 | YR | M | Y | 0.00000 | 20160927 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124653323 | 12465332 | 1 | PS | NIVOLUMAB | NIVOLUMAB | 1 | Intravenous drip | 3 MG/KG, UNK | 125554 | 3 | MG/KG | SOLUTION FOR INJECTION | |||||||
| 124653323 | 12465332 | 2 | SS | NIVOLUMAB | NIVOLUMAB | 1 | Intravenous (not otherwise specified) | 3 MG/KG, UNK | 125554 | 3 | MG/KG | SOLUTION FOR INJECTION | |||||||
| 124653323 | 12465332 | 3 | SS | NIVOLUMAB | NIVOLUMAB | 1 | Intravenous (not otherwise specified) | 3 MG/KG, UNK | 125554 | 3 | MG/KG | SOLUTION FOR INJECTION | |||||||
| 124653323 | 12465332 | 4 | SS | CODEINE PHOSPHATE | CODEINE PHOSPHATE | 1 | Oral | U | 0 | ||||||||||
| 124653323 | 12465332 | 5 | SS | LOXONIN | LOXOPROFEN SODIUM | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124653323 | 12465332 | 1 | Non-small cell lung cancer |
| 124653323 | 12465332 | 4 | Product used for unknown indication |
| 124653323 | 12465332 | 5 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124653323 | 12465332 | DE |
| 124653323 | 12465332 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124653323 | 12465332 | Alanine aminotransferase increased | |
| 124653323 | 12465332 | Aspartate aminotransferase increased | |
| 124653323 | 12465332 | Constipation | |
| 124653323 | 12465332 | Dyspnoea | |
| 124653323 | 12465332 | Gamma-glutamyltransferase increased | |
| 124653323 | 12465332 | Malignant neoplasm progression | |
| 124653323 | 12465332 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124653323 | 12465332 | 1 | 20151221 | 20151221 | 0 | |
| 124653323 | 12465332 | 2 | 20150104 | 20160104 | 0 | |
| 124653323 | 12465332 | 3 | 20150202 | 20160202 | 0 |